
Kluwer Patent Blog

AstraZeneca AB v. EG S.p.A, District Court of Turin (Tribunale di Torino), 14 February 2011

Daniela Ampollini (Trevisan & Cuonzo) · Saturday, June 11th, 2011

The Court of Turin held that Article 68 (1 bis) of the Italian IP Code, which was introduced by Legislative Decree 131 of 13 August 2010, establishing that ‘*Without prejudice to the provision of paragraph 1, companies intending to manufacture pharmaceutical specialties outside patent protection may commence the procedure of registration of the product containing the active ingredient one year prior to the expiry of the supplementary protection or, in absence, the patent claiming the active principle, including any applicable extension*’ does not contravene Article 10 of Directive 2001/83/EC.

Click [here](#) for the full text of this case.

A **full summary** of this case has been published on **Kluwer IP Law**.

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please [subscribe here](#).

Kluwer IP Law

The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how **Kluwer IP Law** can support you.


79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law.

The master resource for Intellectual Property rights and registration.



2022 SURVEY REPORT
The Wolters Kluwer Future Ready Lawyer
Leading change



This entry was posted on Saturday, June 11th, 2011 at 3:12 pm and is filed under [\(Indirect\) infringement](#), [Biologics](#), [Case Law](#), [Italy](#)

You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both comments and pings are currently closed.